Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Abhishek D. Garg, Sanket More, Nicole Rufo, Odeta Mece, Maria Livia Sassano, Patrizia Agostinis, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2017) Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. OncoImmunology 6:12.
Read now
Read now
Laure Aurelian. (2016) Oncolytic viruses as immunotherapy: progress and remaining challenges. OncoTargets and Therapy 9, pages 2627-2637.
Read now
Read now
Jonathan Pol, Aitziber Buqué, Fernando Aranda, Norma Bloy, Isabelle Cremer, Alexander Eggermont, Philippe Erbs, Jitka Fucikova, Jérôme Galon, Jean-Marc Limacher, Xavier Preville, Catherine Sautès-Fridman, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2016) Trial Watch—Oncolytic viruses and cancer therapy. OncoImmunology 5:2.
Read now
Read now
O. Hemminki & A. Hemminki. (2016) A century of oncolysis evolves into oncolytic immunotherapy. OncoImmunology 5:2.
Read now
Read now
Articles from other publishers (37)
Daolin Tang, Rui Kang, Herbert J. Zeh & Michael T. Lotze. (2023) The multifunctional protein HMGB1: 50 years of discovery. Nature Reviews Immunology 23:12, pages 824-841.
Crossref
Crossref
Jia Yi, Peizhe Lin, Qingbo Li, Ao Zhang & Xianbin Kong. (2023) A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon. Molecular Therapy - Oncolytics 30, pages 254-274.
Crossref
Crossref
Saima Sabrina, Yuji Takeda, Tomoyuki Kato, Sei Naito, Hiromi Ito, Yuki Takai, Masaki Ushijima, Takafumi Narisawa, Hidenori Kanno, Toshihiko Sakurai, Shinichi Saitoh, Akemi Araki, Norihiko Tsuchiya & Hironobu Asao. (2023) Initial Myeloid Cell Status Is Associated with Clinical Outcomes of Renal Cell Carcinoma. Biomedicines 11:5, pages 1296.
Crossref
Crossref
Hui Wang, Fulong Nan, Zhou Zeng, Xueming Zhang, Dingxin Ke, Shuyun Zhang, Xiaoqiong Zhou, Delei Niu, Tianyu Fan, Shasha Jiang, Xianjuan Zhang, Yunyang Wang, Bin Wang & Wanming Zhang. (2023) Tumor cell vaccine combined with Newcastle disease virus promote immunotherapy of lung cancer. Journal of Medical Virology 95:2.
Crossref
Crossref
Hai Zou, Xiao‐Zhou Mou & Biao Zhu. (2022) Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic. Global Challenges 7:1.
Crossref
Crossref
Zhi Zhu, A. J. Robert McGray, Weijian Jiang, Binfeng Lu, Pawel Kalinski & Zong Sheng Guo. (2022) Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Molecular Cancer 21:1.
Crossref
Crossref
Shu-Jin Li & Zhi-Jun Sun. (2022) Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead. Cancer Letters, pages 215937.
Crossref
Crossref
Lihong Wang, Louisa S Chard Dunmall, Zhenguo Cheng & Yaohe Wang. (2022) Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment. Journal for ImmunoTherapy of Cancer 10:5, pages e004167.
Crossref
Crossref
Emma J. West, Karen J. Scott, Emma Tidswell, Kaidre Bendjama, Nicolas Stojkowitz, Monika Lusky, Marta Kurzawa, Raj Prasad, Giles Toogood, Christy Ralph, D. Alan Anthoney, Alan A. Melcher, Fiona J. Collinson & Adel Samson. (2022) Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients. Cancers 14:9, pages 2181.
Crossref
Crossref
He Ma, Yang Lu, Zhibin Huang, Saran Long, Jianfang Cao, Zhen Zhang, Xiao Zhou, Chao Shi, Wen Sun, Jianjun Du, Jiangli Fan & Xiaojun Peng. (2022) ER-Targeting Cyanine Dye as an NIR Photoinducer to Efficiently Trigger Photoimmunogenic Cancer Cell Death. Journal of the American Chemical Society 144:8, pages 3477-3486.
Crossref
Crossref
Su Shao, Xue Yang, You-Ni Zhang, Xue-Jun Wang, Ke Li, Ya-Long Zhao, Xiao-Zhou Mou & Pei-Yang Hu. (2022) Oncolytic Virotherapy in Peritoneal Metastasis Gastric Cancer: The Challenges and Achievements. Frontiers in Molecular Biosciences 9.
Crossref
Crossref
Ilkka Liikanen, Saru Basnet, Dafne C A Quixabeira, Kristian Taipale, Otto Hemminki, Minna Oksanen, Matti Kankainen, Juuso Juhila, Anna Kanerva, Timo Joensuu, Siri Tähtinen & Akseli Hemminki. (2022)
Oncolytic adenovirus decreases the proportion of TIM-3
+
subset of tumor-infiltrating CD8
+
T cells with correlation to improved survival in patients with cancer
. Journal for ImmunoTherapy of Cancer 10:2, pages e003490.
Crossref
Crossref
Kerstin Clasen, Stefan Welz, Heidrun Faltin, Daniel Zips & Franziska Eckert. (2021) Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients. Strahlentherapie und Onkologie 198:2, pages 194-200.
Crossref
Crossref
Omeed Moaven, Christopher W. Mangieri, John A. Stauffer, Panos Z. Anastasiadis & Mitesh J. Borad. (2021) Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. JCO Precision Oncology:5, pages 432-441.
Crossref
Crossref
Eftychia Stavrakaki, Clemens M. F. Dirven & Martine L. M. Lamfers. (2021) Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response. Cancers 13:4, pages 614.
Crossref
Crossref
Nasser Hashemi Goradel, Alexander T. Baker, Arash Arashkia, Nasim Ebrahimi, Sajjad Ghorghanlu & Babak Negahdari. (2021) Oncolytic virotherapy: Challenges and solutions. Current Problems in Cancer 45:1, pages 100639.
Crossref
Crossref
Annalisa Adamo, Cristina Frusteri, Maria Teresa Pallotta, Tracey Pirali, Silvia Sartoris & Stefano Ugel. (2021) Moonlighting Proteins Are Important Players in Cancer Immunology. Frontiers in Immunology 11.
Crossref
Crossref
Otto Hemminki, João Manuel dos Santos & Akseli Hemminki. (2020) Oncolytic viruses for cancer immunotherapy. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Vera Kemp, Martine L.M. Lamfers, Gabri van der Pluijm, Bernadette G. van den Hoogen & Rob C. Hoeben. (2020) Developing oncolytic viruses for clinical use: A consortium approach. Cytokine & Growth Factor Reviews 56, pages 133-140.
Crossref
Crossref
Yumi Sakamoto, Tatsuo Okui, Toshiyuki Yoneda, Shoji Ryumon, Tomoya Nakamura, Hotaka Kawai, Yuki Kunisada, Soichiro Ibaragi, Masanori Masui, Kisho Ono, Kyoichi Obata, Tsuyoshi Shimo & Akira Sasaki. (2020) High-mobility group box 1 induces bone destruction associated with advanced oral squamous cancer via RAGE and TLR4. Biochemical and Biophysical Research Communications 531:3, pages 422-430.
Crossref
Crossref
Kevin Harrington, Daniel J. Freeman, Beth Kelly, James Harper & Jean-Charles Soria. (2019) Optimizing oncolytic virotherapy in cancer treatment. Nature Reviews Drug Discovery 18:9, pages 689-706.
Crossref
Crossref
Xiaoyan Shao, Xueke Wang, Xianling Guo, Ke Jiang, Tian Ye, Jianhua Chen, Juemin Fang, Linaer Gu, Sitong Wang, Guirong Zhang, Songshu Meng & Qing Xu. (2019) STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells. Frontiers in Oncology 9.
Crossref
Crossref
Umang Swami, Brian Swick, Yousef Zakharia & Mohammed Milhem. (2019) Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma. Case Reports in Oncological Medicine 2019, pages 1-5.
Crossref
Crossref
Junaid Raja, Johannes M. Ludwig, Scott N. Gettinger, Kurt A. Schalper & Hyun S. Kim. (2018) Oncolytic virus immunotherapy: future prospects for oncology. Journal for ImmunoTherapy of Cancer 6:1.
Crossref
Crossref
Sarah A. Hayes, Stephen Clarke, Nick Pavlakis & Viive M. Howell. (2018) The role of proteomics in the age of immunotherapies. Mammalian Genome 29:11-12, pages 757-769.
Crossref
Crossref
Puja Sharma & Waldemar Debinski. (2018) Receptor-Targeted Glial Brain Tumor Therapies. International Journal of Molecular Sciences 19:11, pages 3326.
Crossref
Crossref
Otto Hemminki, Minna Oksanen, Kristian Taipale, Ilkka Liikanen, Anniina Koski, Timo Joensuu, Anna Kanerva & Akseli Hemminki. (2018) Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy. Molecular Therapy - Oncolytics 9, pages 41-50.
Crossref
Crossref
Yifan Wang, Weiye Deng, Nan Li, Shinya Neri, Amrish Sharma, Wen Jiang & Steven H. Lin. (2018) Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Frontiers in Pharmacology 9.
Crossref
Crossref
Kristian Taipale, Siri Tähtinen, Riikka Havunen, Anniina Koski, Ilkka Liikanen, Päivi Pakarinen, Riitta Koivisto-Korander, Matti Kankainen, Timo Joensuu, Anna Kanerva & Akseli Hemminki. (2018) Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients. Oncotarget 9:5, pages 6320-6335.
Crossref
Crossref
Jacob P. van Vloten, Samuel T. Workenhe, Sarah K. Wootton, Karen L. Mossman & Byram W. Bridle. (2018) Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies. The Journal of Immunology 200:2, pages 450-458.
Crossref
Crossref
Nicole Rufo, Abhishek D. Garg & Patrizia Agostinis. (2017) The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy. Trends in Cancer 3:9, pages 643-658.
Crossref
Crossref
Hiroshi Tazawa, Shinji Kuroda, Joe Hasei, Shunsuke Kagawa & Toshiyoshi Fujiwara. (2017) Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer. International Journal of Molecular Sciences 18:7, pages 1479.
Crossref
Crossref
Zong Sheng Guo, Zuqiang Liu, Stacy Kowalsky, Mathilde Feist, Pawel Kalinski, Binfeng Lu, Walter J. Storkus & David L. Bartlett. (2017) Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Frontiers in Immunology 8.
Crossref
Crossref
Praveen K. Bommareddy, Anand Patel, Saamia Hossain & Howard L. Kaufman. (2016) Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. American Journal of Clinical Dermatology 18:1, pages 1-15.
Crossref
Crossref
Kristian Taipale, Ilkka Liikanen, Anniina Koski, Raita Heiskanen, Anna Kanerva, Otto Hemminki, Minna Oksanen, Susanna Grönberg-Vähä-Koskela, Kari Hemminki, Timo Joensuu & Akseli Hemminki. (2016) Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy. Molecular Therapy 24:7, pages 1323-1332.
Crossref
Crossref
Abhishek D. Garg, Lorenzo Galluzzi, Lionel Apetoh, Thais Baert, Raymond B. Birge, José Manuel Bravo-San Pedro, Karine Breckpot, David Brough, Ricardo Chaurio, Mara Cirone, An Coosemans, Pierre G. Coulie, Dirk De Ruysscher, Luciana Dini, Peter de Witte, Aleksandra M. Dudek-Peric, Alberto Faggioni, Jitka Fucikova, Udo S. Gaipl, Jakub Golab, Marie-Lise Gougeon, Michael R. Hamblin, Akseli Hemminki, Martin Herrmann, James W. Hodge, Oliver Kepp, Guido Kroemer, Dmitri V. Krysko, Walter G. Land, Frank Madeo, Angelo A. Manfredi, Stephen R. Mattarollo, Christian Maueroder, Nicolò Merendino, Gabriele Multhoff, Thomas Pabst, Jean-Ehrland Ricci, Chiara Riganti, Erminia Romano, Nicole Rufo, Mark J. Smyth, Jürgen Sonnemann, Radek Spisek, John Stagg, Erika Vacchelli, Peter Vandenabeele, Lien Vandenberk, Benoit J. Van den Eynde, Stefaan Van Gool, Francesca Velotti, Laurence Zitvogel & Patrizia Agostinis. (2015) Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology 6.
Crossref
Crossref
Jitka Fucikova, Irena Moserova, Linda Urbanova, Lucillia Bezu, Oliver Kepp, Isabelle Cremer, Cyril Salek, Pavel Strnad, Guido Kroemer, Lorenzo Galluzzi & Radek Spisek. (2015) Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Frontiers in Immunology 6.
Crossref
Crossref